Omicron: Covid-19 antibody treatment ‘holds up well’ against new strain, Brii Biosciences says

The developer of China’s first approved Covid-19 antibody cocktail said lab tests had found the treatment “holds up well” against the new Omicron variant, though one of the antibodies had a “substantial drop in activity”.Brii Biosciences on Sunday also again said its therapy “retains activity” against major coronavirus strains including the highly transmissible Delta variant and its sub-lineage Delta Plus.China’s medical products regulator approved its use last Wednesday. The company said the…

Read the original article at South China Morning Post